What is Proofpilot?
Founded in 2014 and headquartered in New York City, Proofpilot operates as a sophisticated software-as-a-service (SaaS) provider dedicated to the modernization of research studies. The company offers a dual-pronged product suite: ProofPilot Rx, tailored for the rigorous demands of life science organizations, and ProofPilot 365, which addresses the growing need for wellness intervention tracking. By automating the design, launch, and participant engagement phases of clinical and wellness research, Proofpilot effectively removes the administrative friction that historically hindered data collection and study scalability. Its market position is defined by its ability to bridge the gap between complex clinical requirements and user-friendly digital interfaces, serving a diverse clientele that ranges from pharmaceutical innovators to wellness-focused enterprises.
How much funding has Proofpilot raised?
Proofpilot has raised a total of $23.4M across 5 funding rounds:
Other Financing Round
$20K
Private Equity
$1.9M
Private Equity
$1.9M
Series B
$12M
Private Equity
$7.7M
Other Financing Round (2014): $20K with participation from Blueprint Health
Private Equity (2014): $1.9M, investors not publicly disclosed
Private Equity (2016): $1.9M supported by Brooklyn Bridge Ventures and Cue Ball Capital
Series B (2022): $12M featuring Sopris Capital Associates, Excelra, First Trust Capital Partners, and Mitsui & Co.
Private Equity (2025): $7.7M, investors not publicly disclosed
Key Investors in Proofpilot
Blueprint Health
A prominent healthcare accelerator focused on nurturing entrepreneurs to develop innovative healthcare IT companies through intensive mentorship and strategic guidance.
Brooklyn Bridge Ventures
A venture capital firm specializing in early-stage investments, providing the foundational support necessary for high-growth technology startups.
Cue Ball Capital
A purpose-driven investment firm that partners with entrepreneurs to create durable, compounding value at the intersection of profit and social impact.
What's next for Proofpilot?
With the infusion of $7.7M, Proofpilot is well-positioned to accelerate its enterprise-level expansion and deepen its technological moat. The company's strategic roadmap likely involves scaling its ProofPilot Rx platform to meet the increasing global demand for decentralized clinical trials and real-world evidence generation. By leveraging its recent capital, the firm is expected to enhance its data analytics capabilities and expand its footprint in the life sciences sector, where the demand for automated, compliant, and participant-centric research tools remains at an all-time high. As the industry shifts toward more agile, digital-first research methodologies, Proofpilot's focus on operational efficiency and participant engagement will be central to its long-term growth and competitive differentiation.
See full Proofpilot company page
